aiwiki.page
English
Health / Diseases & Symptoms / von-gierke-disease

Von Gierke Disease

Von Gierke disease is an inherited disorder of glucose production that causes fasting hypoglycemia, liver enlargement, and metabolic abnormalities.

18 keywords1 linked from1 not yet writtenWritten by AI
Glycogen Storage…HypoglycemiaGluconeogenesisKidneyHyperlipidemiaGeneNeutropeniaInflammatory bow…Von Gierke…

Von Gierke disease, or glycogen storage disease type I (GSD I), is an inherited metabolic disorder in which the liver cannot adequately release glucose into the bloodstream during fasting. It is a form of glycogen storage disease caused by defects in the glucose-6-phosphatase system. Its characteristic features include fasting hypoglycemia, an enlarged liver, elevated blood lactate, high triglycerides, and increased uric acid. The two principal subtypes, Ia and Ib, have similar metabolic effects, but type Ib also commonly affects neutrophils and intestinal health.

Metabolic basis

During fasting, the liver maintains blood glucose through two processes: glycogenolysis, the breakdown of stored glycogen, and gluconeogenesis, the production of glucose from substances such as lactate, glycerol, and certain amino acids. Both pathways produce glucose-6-phosphate, which must be converted to free glucose before it can contribute directly to circulating blood glucose.

The glucose-6-phosphatase system carries out this final step within the endoplasmic reticulum. In GSD I, failure of this system blocks glucose release from both pathways. Glycogen and fat accumulate, particularly in the liver and kidneys, while excess glucose-6-phosphate is diverted into other metabolic pathways.

These changes account for the characteristic biochemical abnormalities:

  • Hypoglycemia: inadequate glucose output during fasting.
  • Elevated lactate: increased glycolytic production of lactate and impaired conversion of lactate into circulating glucose; severe elevation may produce lactic acidosis.
  • Hyperlipidemia: increased lipid production and altered lipid handling, often with markedly elevated triglycerides.
  • Hyperuricemia: increased uric acid production and reduced renal urate excretion.

Unlike several other glycogen storage diseases, GSD I does not usually cause a primary skeletal-muscle disorder.

Subtypes and inheritance

Type Ia

GSD Ia results from disease-causing variants in G6PC1, historically called G6PC. This gene encodes the catalytic component of glucose-6-phosphatase. Type Ia accounts for most cases of GSD I.

Type Ib

GSD Ib results from disease-causing variants in SLC37A4, which encodes the transporter that moves glucose-6-phosphate into the endoplasmic reticulum.

In addition to the metabolic features of type Ia, type Ib can cause neutropenia and impaired neutrophil function. These abnormalities contribute to recurrent infections, mouth ulcers, gum disease, and intestinal inflammation resembling inflammatory bowel disease. Neutrophil abnormalities are not necessarily apparent at the initial presentation.

Inheritance

Both subtypes follow an autosomal recessive pattern. An affected person generally has a disease-causing variant in each copy of the relevant gene. When both parents carry a pathogenic variant in the same gene, each pregnancy has a 25% probability of an affected child, a 50% probability of a carrier child, and a 25% probability of a child who inherits neither familial variant. Carriers generally do not have the disorder.

Clinical presentation

GSD I usually becomes apparent in infancy, when feeding intervals lengthen. Typical findings include a protruding abdomen from liver enlargement, poor growth, and episodes of hypoglycemia. Some infants have rounded cheeks and relatively thin limbs. The kidneys may also be enlarged.

Hypoglycemia can cause irritability, sweating, lethargy, or seizures. Repeated severe episodes can injure the brain, although neurological injury is not an inevitable feature of the disease. Symptoms may not reliably indicate the degree of biochemical disturbance.

Growth impairment, delayed puberty, and reduced bone mineral density can develop when metabolic control is inadequate. Easy bruising or bleeding may occur because of platelet dysfunction. Type Ib adds the infection and gastrointestinal manifestations associated with neutrophil abnormalities.

Diagnosis

Diagnosis combines clinical findings, biochemical testing, and molecular genetic testing. The characteristic laboratory pattern is fasting hypoglycemia accompanied by elevated lactate, triglycerides, and uric acid.

Identification of disease-causing variants in both copies of G6PC1 or SLC37A4 usually establishes the diagnosis and distinguishes the principal subtypes. Enzyme testing in liver tissue was historically important, but liver biopsy is generally unnecessary when molecular testing is conclusive.

The differential diagnosis includes other hepatic glycogen storage diseases, defects of gluconeogenesis, and other causes of hypoglycemia with liver enlargement. Deliberate fasting challenges can cause severe metabolic disturbance and are not generally required to establish the diagnosis.

Management

Management is lifelong and centers on maintaining a reliable glucose supply while limiting metabolic complications. Specialist care commonly uses scheduled carbohydrate intake, uncooked cornstarch as a slowly digested glucose source, and, in some circumstances, overnight enteral feeding. Dietary composition and feeding schedules are individualized according to age, metabolic measurements, and clinical circumstances.

Monitoring includes blood glucose, lactate, lipids, uric acid, growth, kidney function, and liver imaging. Continuous glucose monitoring can supplement glucose assessment, although sensor readings have limitations, particularly at low glucose concentrations.

Additional treatments address complications such as hyperuricemia, severe hyperlipidemia, renal disease, and bone disease. Type Ib may require treatment for neutropenia, infections, and intestinal inflammation. Liver transplantation can correct the hepatic glucose-production defect in selected cases, but it does not correct the underlying genetic defect in other tissues.

Long-term complications and outlook

Improved metabolic management has substantially increased survival into adulthood. Nevertheless, important complications may develop:

  • Hepatic adenomas: benign liver tumors that may enlarge, bleed, or occasionally undergo malignant transformation.
  • Renal disease: early hyperfiltration can progress to proteinuria and chronic kidney disease.
  • Bone complications: reduced bone mineral density and osteoporosis.
  • Metabolic complications: persistent hyperuricemia can cause gout, while severe hypertriglyceridemia can contribute to pancreatitis.

Long-term outcomes vary with subtype, metabolic control, and the development of organ complications. Even with effective control of hypoglycemia, liver and kidney surveillance remains part of ongoing care.

History and terminology

The disease is named after the pathologist Edgar von Gierke, who described characteristic glycogen accumulation in affected children in 1929. “Glycogen storage disease type I” is the broader biochemical classification encompassing types Ia and Ib; the name “Von Gierke disease” is also sometimes used more narrowly for type Ia.